Financial stability is under pressure as total assets declined from $11.6 million in 2025Q3 to $4.6 million in 2026Q1, accompanied by a debt-to-equity ratio of 1.50.
| Total Current Assets | 4.07M | 6.64M | 2.25M | 4.98M | 8.84M | 407.8K | 51.7K |
| Cash & Short-Term Investments | 2.41M | 5.99M | 1.19M | 4.59M | 8.26M | 38.94K | 51.7K |
| Cash Only | 2.41M | 5.99M | 1.19M | 4.59M | 8.26M | 38.94K | 51.7K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 123K | 76K | 97K | 49K | 67K | 0 | 0 |
| Total Non-Current Assets | 537K | 578K | 613K | 277K | 494K | 115.01M | 77.7K |
| Property, Plant & Equipment | 403K | 437K | 560K | 247K | 464K | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 168K | 57K | 0 | 0 | 0 | 115.01M | 0 |
| Other Non-Current Assets | 76K | 84K | 53K | 30K | 30K | 0 | 77.7K |
| Total Assets | 4.6M | 7.21M | 2.86M | 5.26M | 9.33M | 115.41M | 129.4K |
| Asset Turnover | 0.00x | - | - | - | - | - | - |
| Asset Growth % | 513.21% | 152.01% | -45.53% | -43.68% | -91.91% | 89092.47% | - |
| Total Current Liabilities | 4.06M | 2.76M | 3.52M | 2.2M | 1.61M | 348.58K | 29.4K |
| Accounts Payable | 912K | 787K | 929K | 319K | 240K | 0 | 0 |
| Days Payables Outstanding | 36.36K | - | - | - | - | - | - |
| Short-Term Debt | 185K | 182K | 1M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.91M | 1.74M | 644K | 407K | 256K | 348.58K | 29.4K |
| Current Ratio | 1.00x | 2.41x | 0.64x | 2.27x | 5.49x | 1.17x | 1.76x |
| Quick Ratio | 1.00x | 2.41x | 0.64x | 2.27x | 5.49x | 1.17x | 1.76x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 251K | 1.85M | 3.33M | 15.12M | 14.8M | 160.34K | 269.99K |
| Long-Term Debt | 251K | 286K | 2.96M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 337K | 0 | 368K | 59K | 156K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 1.57M | 0 | 15.06M | 14.65M | 160.34K | 269.99K |
| Total Liabilities | 4.31M | 4.61M | 6.85M | 17.31M | 16.41M | 508.92K | 299.39K |
| Total Debt | 436K | 468K | 4.49M | 171K | 271K | 0 | 0 |
| Net Debt | -1.98M | -5.52M | 3.3M | -4.42M | -7.99M | -38.94K | -51.7K |
| Debt / Equity | 1.50x | 0.18x | - | - | - | - | - |
| Debt / EBITDA | 0.04x | 0.04x | - | - | - | - | - |
| Net Debt / EBITDA | -0.19x | -0.47x | - | - | - | - | - |
| Interest Coverage | -2150.17x | -915.08x | -317.35x | -563.00x | -39.75x | - | - |
| Total Equity | 291K | 2.6M | -3.99M | -12.06M | -7.08M | 114.91M | -169.99K |
| Equity Growth % | 429.68% | 165.25% | 66.91% | -70.31% | -106.16% | 67695.3% | - |
| Book Value per Share | 0.90 | 19.58 | -6.39 | -107.91 | -4.23 | 69.62 | -0.10 |
| Total Shareholders' Equity | 291K | 2.6M | -3.99M | -15.48M | -10.66M | 114.91M | -169.99K |
| Common Stock | 46K | 42K | 2K | 1K | 1K | 115M | 298 |
| Retained Earnings | -57.9M | -55.17M | -43.25M | -26.81M | -21.87M | -951.08K | -195.86K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 3.42M | 3.59M | 0 | 0 |
Imminent liquidity and dilution
As reported in financial statements, Silexion Therapeutics' total assets have declined from $11.6 million in 2025Q3 to $4.6 million by 2026Q1, reflecting a rapid depletion of resources that underscores the company's precarious trajectory as it attempts to fund clinical development without a commercial revenue stream.
The consistent contraction of the asset base suggests that the company is consuming its primary liquidity to sustain R&D operations. This trend indicates that the firm's financial health is deteriorating, leaving little room for operational setbacks or delays in clinical trial enrollment.
Based on the 2026Q1 balance sheet, the company holds $2.4 million in cash, a significant reduction from the $9.2 million reported in 2025Q3, which suggests that the firm's liquidity buffer is rapidly evaporating under the pressure of ongoing clinical trial expenditures and administrative overhead.
With a current ratio of 1.00, the company possesses minimal flexibility to manage short-term liabilities without immediate capital infusion. Investors should monitor this liquidity profile closely, as the current cash position appears insufficient to support long-term clinical milestones without further dilutive financing.
According to recent SEC filings, Silexion Therapeutics' equity has plummeted to $291,000 in 2026Q1 from $7.0 million in 2025Q3, a sharp decline that highlights the impact of persistent operating losses and the potential for significant shareholder dilution as the company seeks to replenish its capital base.
The erosion of equity suggests that the company is struggling to maintain a stable capital structure while absorbing continuous losses. This trend may indicate that future financing rounds will likely be highly dilutive, further pressuring the value of existing equity stakes.
As indicated by the balance sheet, the company's debt-to-equity ratio of 1.50 in 2026Q1, combined with the absence of revenue, suggests that the firm's reliance on debt-like instruments and potential grant repayment obligations creates a shadow liability profile that complicates its path to financial sustainability.
The presence of these obligations, alongside the volatility in working capital, implies that headline cash figures may overstate the company's true financial flexibility. Investors should be wary of the potential for these liabilities to trigger repayment events that could further constrain the firm's limited cash resources.
Quick answers to the most common questions about buying SLXN stock.
As of 2025, Silexion Therapeutics Ltd. (SLXN) had total assets of $7.2M including $6.6M in current assets.
Silexion Therapeutics Ltd. (SLXN) carries total debt of $0.5M, offset by $6.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Silexion Therapeutics Ltd. (SLXN) has total shareholders' equity (book value) of $2.6M ($19.58 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Silexion Therapeutics Ltd. (SLXN) reported a current ratio of 2.41x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.